Home » Stocks » Aeolus Pharmaceuticals

Aeolus Pharmaceuticals Inc. (AOLS)

Stock Price: $0.0016 USD 0.0000 (0.00%)
Updated Oct 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 243,338
Revenue (ttm) 771,000
Net Income (ttm) -4.09M
Shares Out 152.09M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 14, 2020
Last Price $0.0016
Previous Close $0.0016
Change ($) 0.0000
Change (%) 0.00%
Day's Open -
Day's Range 0.0016 - 0.0016
Day's Volume 0
52-Week Range 0.0008 - 0.0040

More Stats

Market Cap 243,338
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 152.09M
Float 151.98M
EPS (basic) -0.04
EPS (diluted) -0.03
FCF / Share -0.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 2.15
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.32
PB Ratio 0.81
Revenue 771,000
Operating Income -4.09M
Net Income -4.09M
Free Cash Flow -3.35M
Net Cash 403,000
Net Cash / Share 0.00
Gross Margin -104.41%
Operating Margin -531.00%
Profit Margin -531.00%
FCF Margin -434.89%
ROA -90.30%
ROE -186.43%
ROIC -7,120.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.0016
Target: 1.25
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-33.27%-67.7%145.19%-46.14%51.28%-----
Gross Profit2.083.119.633.937.294.82----
Operating Income-3.27-2.63-0.08-2.70-2.37-3.90-3.64-2.00-2.52-3.30
Net Income-3.56-2.63-0.08-3.210.860.15-25.87-2.30-2.97-3.02
Shares Outstanding14913613510761.5959.4749.1534.7931.9530.24
Earnings Per Share-0.04-0.02--0.03-0.03-0.04-0.53-0.07-0.11-0.10
Operating Cash Flow-3.11-2.440.32-2.97-0.88-3.10-2.45-1.92-1.81-3.08
Capital Expenditures-------0.01---
Free Cash Flow-3.11-2.440.32-2.97-0.88-3.10-2.45-1.92-1.81-3.08
Cash & Equivalents3.160.091.520.870.280.522.360.650.401.73
Total Debt-1.00----0.661.191.170.48
Net Cash / Debt3.16-0.911.520.870.280.521.69-0.55-0.771.24
Book Value3.20-0.851.590.71-20.34-23.26-26.74-1.16-1.041.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aeolus Pharmaceuticals Inc.
Country United States
Employees 4
CEO John L. McManus

Stock Information

Ticker Symbol AOLS
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier OTCMKTS: AOLS
IPO Date February 1, 1996


Aeolus Pharmaceuticals, a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.